Drugs / anti-CD19/BCMA CAR-T cells
anti-CD19/BCMA CAR-T cells
also known as
anti-CD19/CD22 CAR-T cells · Anti-CD19/4-1BB/CD3ζ CAR T-cell · Anti-CD19/BCMA CAR gene vector injection · Anti-CD19/CD20/CD22 CAR T-Cells · Anti-CD19/CD22 CAR NK Cells · bi-specific CD19-CD22 CAR-T therapy · CD19-CD22 bi-specific CAR-T therapy · CD19-CD22 CAR-T cells
Cell therapy targets CD19, CD22 via depletion
Trials 8
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD19/BCMA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03879382 ↗ |
| Known as | Anti-CD19/4-1BB/CD3ζ CAR T-cell | “Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd...” NCT03938987 ↗ |
| Known as | Anti-CD19/BCMA CAR gene vector injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07121777 ↗ |
| Known as | Anti-CD19/CD20/CD22 CAR T-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05418088 ↗ |
| Known as | Anti-CD19/CD22 CAR NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824964 ↗ |
| Known as | anti-CD19/CD22 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04303520 ↗ |
| Known as | bi-specific CD19-CD22 CAR-T therapy | “Collectively, our data advocate for the potential role of bi-specific CD19-CD22 CAR-T therapy in addressing r/r B-ALL.” PMID 40719826 ↗ Jul 2025 |
| Known as | CD19-CD22 bi-specific CAR-T therapy | “In this study, we present both pre-clinical and clinical findings from an ongoing trial (NCT04303520) assessing the therapeutic efficacy of the CD19-CD22 bi-specific CAR-T...” PMID 40719826 ↗ Jul 2025 |
| Known as | CD19-CD22 CAR-T cells | “Pre-clinical data from animal models reveal that CD19-CD22 CAR-T cells effectively induce cytotoxicity, thus suppressing B-ALL cell proliferation.” PMID 40719826 ↗ Jul 2025 |
| Action | Deplete | “bi-specific CAR-T immunotherapies targeting both CD19 and CD22 may offer enhanced efficacy in eliminating r/r B-ALL” PMID 40719826 ↗ Jul 2025 |
| Modality | Cell therapy | “Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs” NCT03706547 ↗ |
| Route | Intravenous | “CAR T-cell intravenous, single dose administration on Day 0” NCT03938987 ↗ |
| Target | CD19 | “anti-CD19 and anti-BCMA CARs” NCT03706547 ↗ |